[go: up one dir, main page]

HN2003000051A - Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico. - Google Patents

Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico.

Info

Publication number
HN2003000051A
HN2003000051A HN2003000051A HN2003000051A HN2003000051A HN 2003000051 A HN2003000051 A HN 2003000051A HN 2003000051 A HN2003000051 A HN 2003000051A HN 2003000051 A HN2003000051 A HN 2003000051A HN 2003000051 A HN2003000051 A HN 2003000051A
Authority
HN
Honduras
Prior art keywords
butilbencil
piridin
terc
amino
acid
Prior art date
Application number
HN2003000051A
Other languages
English (en)
Inventor
Kimberly O' Keefe Cameron
Kim Anne Johnson
Bruce Allen Lefker
Chandra Aggarwal Prakash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN2003000051A publication Critical patent/HN2003000051A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A METABOLITOS DEL ACIDO (3-{[4-TERC-BUTILBENCIL)-(PIRIDIN-3-SULFONIL)AMINO}METIL] FENOXI)ACETICO. LA PRESENTE INVENCION SE REFIERE TAMBIEN A PROCEDIMIENTOS DE TRATAMIENTO DE LA OSTEOPOROSIS Y DE AYUDA A LA CURACION DE FRACTURAS OSEAS UTILIZANDO UN METABOLITO DEL ACIDO (3-{[4-TERC-BUTILBENCIL)-PIRIDIN-3SULFONIL)AMINO]METIL}FENOXI)ACETICO. ADEMAS LA PRESENTE INVENCION SE REFIERE A PROCEDIMIENTOS DE DETERMINACION DE SI SE HA ADMINISTRADO A UN PACIENTE ACIDO (3-{[4-TERC-BUTILBENCIL) - (PIRIDIN-3-SULFONIL)AMINO] METIL} FENOXI)ACETICO.
HN2003000051A 2002-01-31 2003-01-28 Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico. HN2003000051A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31

Publications (1)

Publication Number Publication Date
HN2003000051A true HN2003000051A (es) 2003-09-24

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000051A HN2003000051A (es) 2002-01-31 2003-01-28 Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico.

Country Status (29)

Country Link
US (1) US6852863B2 (es)
EP (1) EP1470109A1 (es)
JP (1) JP2005521668A (es)
KR (1) KR20040077884A (es)
CN (1) CN1625549A (es)
AP (1) AP2004003094A0 (es)
AR (1) AR038332A1 (es)
BR (1) BR0307339A (es)
CA (1) CA2473984A1 (es)
EA (1) EA200400724A1 (es)
EC (1) ECSP045215A (es)
GB (1) GB2400100B (es)
HN (1) HN2003000051A (es)
HR (1) HRP20040683A2 (es)
HU (1) HUP0500012A2 (es)
IL (1) IL162167A0 (es)
IS (1) IS7281A (es)
MA (1) MA27169A1 (es)
MX (1) MXPA04004960A (es)
NO (1) NO20043569L (es)
OA (1) OA12760A (es)
PA (1) PA8564601A1 (es)
PE (1) PE20030978A1 (es)
PL (1) PL371982A1 (es)
TN (1) TNSN04138A1 (es)
TW (1) TW200302080A (es)
UY (1) UY27632A1 (es)
WO (1) WO2003064391A1 (es)
ZA (1) ZA200404067B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US7666330B2 (en) * 2005-04-20 2010-02-23 Lg Chem, Ltd. Additive for non-aqueous electrolyte and secondary battery using the same
KR101088942B1 (ko) * 2006-07-28 2011-12-01 화이자 프로덕츠 인코포레이티드 Ep2 작용제
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JP5136640B2 (ja) * 2008-03-12 2013-02-06 宇部興産株式会社 ピリジルアミノ酢酸化合物
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
PL2415763T3 (pl) 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
EA200400724A1 (ru) 2004-12-30
US20030216445A1 (en) 2003-11-20
AR038332A1 (es) 2005-01-12
HRP20040683A2 (en) 2004-10-31
PA8564601A1 (es) 2003-09-05
GB0413967D0 (en) 2004-07-28
CN1625549A (zh) 2005-06-08
GB2400100B (en) 2006-04-12
IL162167A0 (en) 2005-11-20
GB2400100A (en) 2004-10-06
NO20043569D0 (no) 2004-08-26
BR0307339A (pt) 2004-12-07
US6852863B2 (en) 2005-02-08
UY27632A1 (es) 2003-08-29
EP1470109A1 (en) 2004-10-27
MA27169A1 (fr) 2005-01-03
NO20043569L (no) 2004-08-26
KR20040077884A (ko) 2004-09-07
WO2003064391A1 (en) 2003-08-07
AP2004003094A0 (en) 2004-09-30
MXPA04004960A (es) 2005-04-08
IS7281A (is) 2004-05-21
HUP0500012A2 (hu) 2005-04-28
CA2473984A1 (en) 2003-08-07
ECSP045215A (es) 2004-09-28
JP2005521668A (ja) 2005-07-21
PE20030978A1 (es) 2003-11-19
PL371982A1 (en) 2005-07-11
ZA200404067B (en) 2005-08-29
TW200302080A (en) 2003-08-01
OA12760A (en) 2006-07-04
TNSN04138A1 (fr) 2007-03-12

Similar Documents

Publication Publication Date Title
HN2003000051A (es) Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico.
SE0100568D0 (sv) Compounds
MXPA04000599A (es) Derivados del acido indan acetico y su uso como agentes pharmaceuticos, intermediarios, y metodo de preparacion.
BRPI0416628A (pt) uso de compostos orgánicos
EA200500715A1 (ru) Новые лекарственные средства для лечения хронического обструктивного заболевания лёгких
UA86977C2 (ru) Производные гидантоина для лечения обструктивных болезней дыхательных путей
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
MX2010010505A (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
ATE545407T1 (de) Pharmazeutische formulierung von apomorphin für die bukkale verabreichung
HK1108835A1 (en) Octenidine-containing lozenges used against inflammatory oral and pharyngeal diseases
WO2003079993A3 (en) hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
WO2007120557A3 (en) Method and apparatus of low strengh electric field network-mediated delivery
SE0100566D0 (sv) Compounds
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
MXPA06013039A (es) El tratamiento de enfermedad respiratoria.
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
HK1125386A1 (en) Human semen enhancer of viral infection peptides (sevi) and their use
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
SE0101692D0 (sv) Compounds
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
IL181908A (en) Method for maturation of oocytes using il-17
SG156658A1 (en) Treatment of diseases